RxDoctor Payments Data

James Marczak, PA

Physician Assistant · Glendale, AZNPI 1720123805

Payments from drug & device makers

$6,580in general payments, 2019–2025

Across 196 payments — averaging $33.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$970
  • Biohaven Pharmaceuticals, Inc.$832
  • Novo Nordisk$690
  • Abbott$470
  • Amgen$434
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$80012%
  • Food & beverage$5,78088%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,580 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$9,307
Medicare patients
29
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$26,361
EliquisApixaban20$13,425
RybelsusSemaglutide11$9,095
MyrbetriqMirabegron18$8,283
Metoprolol Succinate57$734
Albuterol Sulfate HfaAlbuterol Sulfate19$612
Gabapentin40$553
Levothyroxine Sodium68$548
Atorvastatin Calcium81$462
Oxybutynin Chloride ErOxybutynin Chloride15$454
Lisinopril54$367
Duloxetine Hcl32$318
Fluticasone Propionate28$318
Rosuvastatin Calcium46$305
Amlodipine Besylate43$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$690$35,45634 claims
PfizerEliquis$270$13,42520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →